The 'at least as good as' criterion, introduced by Laster and Johnson for a continuous response variate, is developed here for applications with dichotomous data. This approach is adaptive in nature, as the margin of non-inferiority is not taken as a ÿxed di erence; it varies as a function of the positive control response. When the non-inferiority margin is referenced as a high fraction of the positive control response, the procedure is seen to be uniformly more e cient than the ÿxed margin approach, yielding smaller sample sizes when sizing non-inferiority trials under identically speciÿed conditions. Extending this method to proportions is straightforward, but highlights special considerations in the design of non-inferiority trials versus superiority trials, including potential trade-o s in statistical e ciency and interpretability.
INTRODUCTION
The general framework for non-inferiority testing initially proposed by Blackwelder [1] is now well established and has been explored by a number of authors [2] [3] [4] . Brie y, the test requires that the e ect of a new therapy be no more than a ÿxed amount, 'delta' ( BW ), worse than the e ect of an active control. Recent extensions include 'adaptive' testing methods that allow the non-inferiority margin to vary as a function of the active control response [5] [6] [7] . In particular, the method proposed by Laster and Johnson [5] describes the statistical advantage of expressing the margin as a percentage of the control response, referred to as the 'at least as good as' criterion, based on the mean of a continuous response variable. We now develop this method for application to dichotomous data and, in the process, examine both statistical and practical aspects of its use. Extending this method to proportions is straightforward, but highlights special considerations in the design of non-inferiority trials versus superiority trials, including potential trade-o s in statistical e ciency and interpretability.
Blackwelder [1] introduced a single-sided null hypothesis for clinical inferiority to be rejected in favour of the at least as good as hypothesis, deÿned in terms of a dichotomous outcome variable, with higher proportions denoting greater success, as
where st and et are success proportions with standard and experimental therapies and BW represents the clinical tolerance selected. A trial designed in this framework would be successful if the outcome with the test therapy (et) were no worse than the outcome with the active control (st), by some clinically tolerable amount, BW , usually envisioned as a small fractional part of the e ect attributed to the active control.
Blackwelder assumes that st (the success rate of a standard therapy) is far enough from 0 or 1, given su ciently large sample sizes, that its estimate p st is distributed approximately normal. Under H 0 , with BW 
where p st and p et are simply the observed experimental proportions. It should be noted that Blackwelder's large sample-based choice for s 2 , when dealing with the null distribution of the di erence between two independently distributed proportions, was not without controversy. See References [8, 9] . We feel the unpooled version (3) is consistent with the conditions imposed by non-inferiority testing. Farrington and Manning [2] examined several comparative forms for s 2 for use with dichotomous data in non-inferiority trials and suggest that maximum likelihood estimates would be more accurate in establishing the null variance. Phillips [6] argues that with large samples, asymptotic arguments should su ce to allow the use of observed proportions and presents non-inferiority trial formulae on this basis. In essence, Phillips uses the Blackwelder (unpooled) s 2 when comparing the di erence in proportions with a constant ( BW ) for clinical tolerance.
In this paper, as in Reference [5] , Blackwelder's approach of testing et against st − BW will be recast as a test of et against a lower bound, a high percentage or fraction (R LB ) of st (R LB ¡1). In this format, the null and alternative hypotheses take the form
where higher proportions denote greater success.
The relationship between et and st may be characterized by their ratio as R True = et = st . This parameter (R T ) is useful for planning non-inferiority trials as it allows one to quantify the e ectiveness of the new therapy in direct relation to expected e cacy of the active comparator.
In this format, the null and alternative hypotheses would have the form
HYPOTHESIS TESTING
Blackwelder's approach in (1) is identically equivalent to the high-fraction approach in (4) when st − BW = R LB st , or
Note, as in Reference [1] , to justify the as least as good as application, BW must be positive, and thus R LB ¡1 as deÿned here. As Blackwelder points out, BW could in theory be zero or negative, thus R LB ¿1, but these cases are uncommon for non-inferiority testing. More typically, when BW is selected as a small part of st , R LB st is the complementary larger part of it. Our large sample formulations for the test statistics considered in this paper will rely on the experimentally observed proportions as in References [1, 6] . Unconditionally based exact tests for non-inferiority are available and are discussed below. The sample-based contrasts and their variances for both approaches (Blackwelder and the high-fraction approach) are as follows.
For Blackwelder,
with
by independence. For the high-fraction lower-bound approach
Therefore, when R LB ¡1,
The resulting relative e ciency follows from the direct translation (mapping) between the two equivalent forms of contrasts and the usual assumptions considered for independent random variables. In this form, the resultant test statistic is asymptotically normal as
where here, higher proportions denote greater success. Phillips [6] conÿrms the form of this test statistic produced for an adaptive test for non-inferiority. The adaptive nature of Laster and Johnson's test for continuous data [5] as derived here for proportions, and Phillips' test [6] , arises from the fact that the margin for non-inferiority varies as a function of the positive control response.
As noted by Phillips [6] , similar results are obtained using a conÿdence interval based on the same Var(p et − R LB p st ) as
If a conÿdence interval procedure were applied to exclude BW based on the unpooled Var(p st − p et − BW ) seen in (8), it would not produce the same results, generally, relative to the conÿdence interval seen in (12a) using Var(p et − R LB p st ), for it would have the wrong size and be generally ine cient (given R LB ¡1). A similar phenomenon was pointed out in Reference [5] using continuous data. The ine ciency of Blackwelder's hypothesis test in (11) , in similar circumstances, also pertains to the associated conÿdence interval procedure.
SAMPLE SIZE REQUIREMENTS
For studies large enough to justify the normal approximation, the variance of (p et − p st R LB ) shown in (10) leads to
where st and et are the success proportions with standard and experimental therapies, R T = et = st , R LB the lower bound (high fraction, R LB ¡R T ) with Z 1− and Z ÿ the normal deviates, producing the chosen single-sided probabilities under the operationally speciÿed hypotheses
Phillips [6] conÿrms the form of (13a) as a special case of a more general sample size equation produced for an adaptive test for non-inferiority. A special case occurs as well, when et = st = or R T = 1, where (13b) can then be rewritten as
The above formulae rely on asymptotic arguments in using the usual normal approximations. Phillips [6] argues that studies that typically enrol 100-200 or more patients per treatment group, with success rates below 95 per cent, should hold up reasonably well, so that the size of the test is near the nominal -level.
COMPARATIVE EFFICIENCY
With continuous data in Reference [5] , an e ciency ratio was derived to compare the sample size requirements for the high-fraction and Blackwelder approaches. The high-fraction approach was found to be uniformly more e cient than Blackwelder's method when R LB ¡1, yielding smaller sample sizes for non-inferiority trials under commonly speciÿed conditions. With a dichotomous outcome variable, two versions of the e ciency ratio result from a comparison of sample sizes under di erent assumptions for R T (EF a and EF b ). In the general case with no restriction on R T ,
whereas in the special case of R T = 1 (or et = st = ),
This form (15b) for the e ciency ratio is identical to the version produced for continuous data in Reference [5] . In either case, the relative e ciency of the high-fractioned test found with continuous data remains uniformly (when R LB ¡1) in the case of proportions, as indicated above by (11) .
DEALING WITH PROPORTIONS OF FAILURE
Note that in the original work [5] with continuous data, whenever smaller values denote improvement, the ratio R T may be inverted (as st = et ) for testing against a lower bound, to maintain the advantage of improved e ciency. We will make the same suggestion here. When dealing with failure data or the like, simply redeÿne R T as
This will allow the continued use of the lower bound R LB (¡1) to insure the increased e ciency whenever smaller values denote improvement. When this inverted deÿnition for R T is used, changes will be required in the statements involving hypotheses, test statistics, and e ciency equations. Sample size formulations, with the exception of R T = R T = 1, will require changes as well. The null and alternative hypotheses would then be rewritten as
when lower proportions denote greater success. The test statistic in like fashion, would be
Sample size equations would be modiÿed (R T =1) to
with R T = st = et . Similar substitutions would be required to right the e ciency equations as well. Note that with failure data as described here, Blackwelder equivalence is referenced to the experimental therapy as BW = (1 − R LB ) et . Tables I and II display corresponding sample size (per group) requirements for both success and failure data (respectively), when testing lower bounds on non-inferiority (R LB ) of up to 95 per cent 'as good as' (with 80 per cent power; one-tailed = 0:05). To demonstrate sample sizes with similar critical regions for the lower-valued proportions in either set of tables, an R LB of 50 per cent is included. The savings in sample size associated with the high-fractioned approach versus Blackwelder's method (up to 39 per cent for R LB = 0:75 to 0.95, and up to 69 per cent for R LB of 0.50, under the conditions examined in Tables I and II) makes it an attractive option for planning non-inferiority studies, and, as illustrated in the next section, adds a new dimension to the study planning process.
STUDY DESIGN SCENARIOS
We illustrate the use of this method for planning a study when various hypothesis-testing strategies are under consideration. Suppose a new dental gel is to be investigated for use as a topical anaesthetic during periodontal scaling and subgingival curettage. Pain severity will be assessed on a 5-point scale, with control of pain dichotomized as either success (scores of 0 or 1) versus failure (scores of 3, 4 or 5). The sponsor believes that the new product is at least as e ective as a standard, marketed agent in controlling pain, with a faster acting e ect. In previous placebo-controlled studies, the marketed product demonstrated a 70 per cent success rate in patients with advanced periodontitis, on the basis of the same pain assessment scale. The sponsor will employ a randomized, double-blind, parallel-group design to compare the new product to placebo as well as an active control (the standard, marketed anaesthetic) in the same target population. To establish e cacy, the study must demonstrate that the new treatment is superior to placebo and not inferior to the active control. To fully validate the outcome of the study, response to the active control must also be superior to placebo. Weighing both cost and regulatory concerns, we evaluate sample size requirements under a number of di erent, but equally plausible assumptions and hypothesis-testing frameworks.
Non-inferiority trials
Prior studies in this periodontal maintenance setting indicate that a di erence in success rates of 16 per cent (treatment-70 per cent versus placebo-54 per cent) is a clinically meaningful e ect. To detect this di erence and demonstrate superiority of each active treatment over placebo, with two-tailed = 0:05 and ÿ = 0:2 (80 per cent power), the required sample size per group would be n per group ≈ 141 using equation (13a) with R LB = 1 (which yields the usual sample size formula for superiority based on the variance in (3) above).
Note, a continuity correction is not used here. Furthermore, adjustment of the -level is unnecessary for all three hypotheses proposed must be rejected to meet the requirements of the study (see Reference [10] ).
For non-inferiority, we set R LB = 0:80 to determine if the new product is at least 80 per cent as e ective as the standard, keeping = 0:05 (one sided in this instance) and ÿ = 0:2. Using equation (14) Table I )
This sample size for testing non-inferiority is smaller than that required for testing superiority (n = 141), even though a smaller di erence is sought (0.14 for non-inferiority versus 0.16 for superiority). Two reasons explain the di erence in sample size requirements: use of the singlesided rejection region and a smaller variance. By comparison, Blackwelder's n per group = 132, for the same non-inferiority margin (again 0.14 or 0.2(0.7)), with a single-tailed rejection region as well (see Table I ). Clearly, if the study were sized for a test of superiority, it would have more than adequate power to establish non-inferiority under the assumed conditions (once again, no adjustment for multiple comparisons has been made). Note in particular that, if R LB = 0:8 were considered too lenient, higher limits could be considered, but sample sizes will soar. This is illustrated in the following table (from Table I 
Non-inferiority versus Superiority
There is often limited evidence, or only a theoretical basis, for assuming that the new product will out-perform the active control, and the magnitude of the di erence is usually uncertain. This debate often gives rise to the following question: What e ect size in superiority could be detected with identical type 1 error (adjusted for two-tailed hypothesis testing) and type 2 error, with sample sizes similar to those just determined for a non-inferiority test, if the new therapy were, in fact, better than the active control (R T ¿1)? Returning to the above example, suppose the sponsor suspects that the new dental gel is more e ective than the active control, to some marginal degree. What would be the case for testing superior performance based on an assumed 10 per cent or even a 20 per cent improvement in response (e.g. R T = 1:1 or 1.2), thus e cacies of about 77 per cent or 84 per cent, respectively? Again, with two-tailed = 0:05 and 80 per cent power, the required sample sizes per group (based on the superiority form of equation (13a) with R LB = 1) would be n (RT=1:1) = 619 and n (RT=1:2) = 138 in order to detect di erences in success rates of 7 or 14 per cent (respectively). In this instance, when the new product o ers a relatively small beneÿt (R T = 1:1) over standard therapy, the sample size adequate for testing non-inferiority provides insu cient power for a test of superiority. By contrast, Table I indicates that n per group = 110 would be su cient to demonstrate that the new dental gel is at least '90 per cent as good as' (not superior to) the active comparator if, in fact, R T = 1:1. With R T = 1:2, n per group = 65 would su ce to make a '95 per cent as good as' claim. Again, the sample size of n = 141 per group required for testing superiority against placebo (with R T = 1:0) would fulÿl power requirements for these other hypothesis tests as well.
The upshot of these considerations is clear based on the assumptions R T = 1:1 or 1.2. Raise the sample size to establish the superiority claim (n ≈ 619 or 138 per group, respectively), or instead, keep costs down and design a non-inferiority trial (n = 110 or 65 per group) to establish that the new dental gel is at least 90 or 95 per cent (respectively) as good as the active control product. If the R T = 1 assumption is considered more realistic, the 80 per cent as good as design, with n = 141 per group, would cover all of the above with the exception of the superiority case for R T = 1:1.
Typically, the choice depends on ÿnancial considerations and the degree of acceptable risk. A relatively safe strategy is to size the study for superiority while proposing a high-fractioned non-inferiority trial (at 90 per cent or 95 per cent). Even if the study failed to demonstrate superiority, it could still support a claim that the new product is 'at least as good as' the active control. This ability is built into the non-inferiority paradigm. It could be argued that the strategy generates a potential multiplicity concern, allowing two ways to succeed in claiming signiÿcance: superiority or non-inferiority. However, Morikawa and Yoshida [10] demonstrate, on the basis of closed hypothesis-testing procedures (CTP), that no adjustment of the -level is required. That is, if superiority were to be established, non-inferiority is contained in that result; thus by CTP, no adjustment to the type 1 error is required even if only non-inferiority is obtained.
INTERPRETING STUDY RESULTS
To perform the non-inferiority test at study completion, the observed proportions p et and p st are used to construct the following test statistic (12) which, if larger than the single-sided critical constant Z , allows us to reject H 0 :
et − R LB st 60 and infer that the experimental therapy is at least as good as the standard therapy by an amount exceeding (R LB × 100) per cent.
We illustrate the use of this test in the context of the above example. Let us say the sponsor sizes the study to detect superiority of each active treatment over placebo, and to perform the non-inferiority test based on R T = 1, with a prescribed lower bound of R LB = 0:8 (80 per cent as good as). This approach yields a sample size of 141 per group (or 423 total for the three-arm trial), since the larger number required for superiority testing supersedes the smaller number needed to evaluate non-inferiority.
It should be noted that in those instances where no superiority justiÿcations are required, thus only the two-arm demonstration of non-inferiority, the smaller sample size would su ce. Non-inferiority test (high fractioned equation (12) The trial succeeds in establishing non-inferiority based on 80 per cent as good as, and in both tests of superiority. Note, as mentioned above, no control of the joint -level is required.
A di erent scenario
Now consider results if the new drug performed considerably better than the active control. That is, suppose the success rates were 87 per cent in the new drug group, 69 per cent with active control, and 54 per cent in the placebo group.
Group p success (per cent)
New dental gel 87 Active control 69 Placebo 54
In this scenario, the new drug is statistically signiÿcantly more e ective than the active control (p¡0:0001, two sided). Based on CTP as discussed above, the claim of superiority is justiÿed, despite the fact that the trial was designed with a non-inferiority objective. Clearly, non-inferiority is subsumed under the alternative hypothesis for superiority. The superiority of the active control over placebo (p¡0:0001, two sided) further validates the e cacy of the new product.
Once again, it could be more cost-e ective to plan the study as a non-inferiority trial, assuming that the test product o ers a small but realistic advantage over the active control. This conservative approach allows for a broader range of successful trial outcomes, spanning both non-inferiority and superiority claims. Given the possible scenarios noted above, it would be prudent to size a study for superiority testing, while proposing a high-fraction non-inferiority margin for the primary hypothesis test. Such an approach has minimal associated risk, with the maximum chance for a successful marketing claim.
DISCUSSION
The at least as good as criterion previously developed for continuous data has similar advantages in the case of binomial endpoints. It has been shown under typical conditions for use in non-inferiority trials (i.e. where R LB ¡R T and R LB ¡1), that the hypothesis test based on the high-fraction format H 0 : et − R LB st 60 is more powerful than Blackwelder's test of H 0 : st − et ¿ BW to detect any given alternative hypothesis contained in
The increased e ciency is a result of smaller SE's for contrasts deÿned by the high-fraction hypothesis test (R LB ¡1) compared to their Blackwelder equivalents.
We have also suggested a strategy to evaluate the e ect size that can be detected in a superiority trial of the same sample size required to support non-inferiority claims, with type 1 and type 2 errors held constant. As illustrated, study planners can explore a range of study scenarios and examine trade-o s with the use of at least as good as and superiority designs, when patient resources are limited and the merits of the new therapy versus standard are uncertain.
Although we illustrate the method using e cacy response rates, the high-fraction approach to trial planning is particularly useful for non-inferiority tests involving safety outcomes, including event rates for toxicity. Oncology and critical care studies are attractive settings for this procedure, given the high mortality typical of such studies and the need to examine clinical beneÿts of new therapies on morbidity or quality of life. For instance, a drug may not be expected to improve survival but could prolong the duration of tumour response or delay the need for narcotics to control pain. The objective of such studies may be to assure that the new therapy has no adverse impact on mortality (e.g. survival of patients administered the new therapy should be at least 95 per cent of survival with standard care), while the new therapy is shown to o er a signiÿcant advantage in terms of other important clinical outcomes.
The selection of a non-inferiority margin that is 'adaptive' to the control group response o ers many advantages. First, study planners often ÿnd it simpler to agree upon the 'per cent as good as' or 'high-fractional part' of the positive control e ect that the new product must achieve, than to select an absolute value for clinical tolerance (Blackwelder's BW ). Expressing non-inferiority as a high numerical fraction of the expected active control response yields a more e cient testing procedure, and thus, savings in sample size. In addition, there are certain advantages in using a percentage lower bound for testing non-inferiority at the conclusion of the study. If the control response is not predicted accurately, the amount of inferiority considered tolerable may no longer be a meaningful value ( BW ) in relation to the observed control response. By contrast, the percentage lower bound (R LB ) can always be used for hypothesis testing, and will typically be a relevant threshold for non-inferiority, regardless of the magnitude of observed positive response in the control group. In this sense, the method is adaptive as seen in Reference [6] . Further, when conducting hypothesis tests for multiple related outcome variables, the application of the same high fraction of the standard as a general criterion for testing non-inferiority, will enhance the credibility of the analysis. It avoids pre-specifying di erent (and sometimes arbitrary) -values for each outcome variable to deÿne clinical tolerance and allows for a consistent interpretation of the study.
Phillips [6] addresses the value of the adaptive lower bound R LB by indicating its analogy with BW as 'ÿxed in advance by the experimenter', and thus not dependent on the observed success rates. He points out, further, that his work has indicated no discontinuities in the size or power functions for these adaptive methods.
Regardless of the approach to non-inferiority testing, there is potential loss of power if the control group response is not predicted accurately. It is important to review past performance of the active control treatment in previous placebo-controlled trials in order to assess the constancy and reproducibility of its e ect relative to placebo. The 'constancy assumption' can be critical to the interpretation of e cacy in non-inferiority trials, as it would require that the size of the active control e ect be bounded by its e ect size in historical placebocontrolled trials. See the ICH guidelines [11] and Hung et al. [12] for more in-depth coverage of this topic.
The scenarios presented in this paper underscore the advantage of nominally designating high-fractioned non-inferiority objectives for clinical trials that are, in fact, adequately powered to demonstrate clinical superiority. Insofar as the results support non-inferiority, at a minimum, the trial will be successful. However, this approach also allows for a claim of superiority if treatment e ects emerge as anticipated. Clearly, this approach should only be taken if the new product is believed to be superior to the active control. It would absurd to plan a non-inferiority study with R T greater than 1 (speciously), purely for the purpose of decreasing the sample size, as this would lead to gross under-powering of the study.
A NOTE ON EXACT AND CONTINUITY-CORRECTED TESTS OF NON-INFERIORITY
Exact tests are usually considered for small samples, when asymptotic normality may be in question. Farrington and Manning [2] remind us that an exact test of null hypotheses for proportions with non-zero di erences (or non-unity relative risks) does not exist, thus providing no absolute reference to compare di erent methods. To be clear, there is in fact no permutation-based exact test conditional on the actual observations in an experiment when non-zero centred null hypotheses are involved (or non-unity relative risks). See Reference [13] . Chan [14] has discussed unconditional exact tests of non-inferiority for smaller data sets using the unconditional Z statistic described by Farrington and Manning [2] . Since non-inferiority testing with proportions conditionally has no exact test basis with nonzero centred null hypotheses and Chan's exact unconditional approach [14] does not require the continuity adjustment, such corrections were not applied in these examples. No mention or
